Critical Review: Allarity Therapeutics (ALLR) versus The Competition

Allarity Therapeutics (NASDAQ:ALLR) is one of 618 publicly-traded companies in the “MED – BIOMED/GENE” industry, but how does it compare to its peers? We will compare Allarity Therapeutics to related businesses based on the strength of its dividends, valuation, earnings, analyst recommendations, profitability, institutional ownership and risk.

Analyst Ratings

This is a summary of current recommendations and price targets for Allarity Therapeutics and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allarity Therapeutics	1	0	1	0	2.00
Allarity Therapeutics Competitors	5309	11897	37053	1114	2.61

Allarity Therapeutics currently has a consensus price target of $9.25, suggesting a potential upside of 537.93%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 60.97%. Given Allarity Therapeutics’ higher possible upside, analysts clearly believe Allarity Therapeutics is more favorable than its peers.

Risk & Volatility

Allarity Therapeutics has a beta of 0.22, meaning that its stock price is 78% less volatile than the S&P 500. Comparatively, Allarity Therapeutics’ peers have a beta of 0.97, meaning that their average stock price is 3% less volatile than the S&P 500.

Profitability

This table compares Allarity Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Allarity Therapeutics	N/A	-173.31%	-102.57%
Allarity Therapeutics Competitors	-1,412.64%	-642.54%	-28.25%

Institutional & Insider Ownership

11.5% of Allarity Therapeutics shares are held by institutional investors. Comparatively, 51.1% of shares of all “MED – BIOMED/GENE” companies are held by institutional investors. 0.1% of Allarity Therapeutics shares are held by insiders. Comparatively, 13.7% of shares of all “MED – BIOMED/GENE” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Allarity Therapeutics and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Allarity Therapeutics	N/A	-$24.51 million	-0.18
Allarity Therapeutics Competitors	$930.65 million	-$45.04 million	10.89

Allarity Therapeutics’ peers have higher revenue, but lower earnings than Allarity Therapeutics. Allarity Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Allarity Therapeutics peers beat Allarity Therapeutics on 9 of the 13 factors compared.

Allarity Therapeutics Company Profile

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.